Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target

Guggenheim analyst Yatin Suneja has reiterated a Buy rating on Abivax (NASDAQ: ABVX) and maintained a price target of $175 for the stock. This endorsement suggests confidence in the company's future performance.